Gaussem Pascale

PU-PH, AP-HP, Director of INSERM unit 1140

Research theme : Theme 2 – Parts 1 and 2

Phone: 01 53 73 99 39


Director of INSERM unit 1140, Faculty of Pharmacy of Paris. PU-PH, Professor of Haematology at University Paris Descartes. Head of Haematology Clinical Laboratory at Hôpital Européen Georges Pompidou, Paris.

The main mission of UMR_S1140 is to develop new therapeutic strategies in haemostasis and cardiovascular diseases through the improvement of knowledge in the field of molecular mechanisms of haemostasis and vasculogenesis, and of management of antithrombotic drugs to decrease drug-related adverse events with strong clinical application potential.

I coordinate the Theme 2 “Haemostasis and antithrombotics agents” and am particularly involved in the following research topics: (i) identification of regulatory mechanisms of platelet formation and activation in relation to the cAMP/cGMP system, (ii) pharmacology of antiplatelet and anticoagulant agents, analysis of the causes of variability of the response to these agents, definition of the management of associated hemorrhages, and research on their neutralization and development of rapid dosing methods.


  • Pharmacist Degree, Paris XI University, 1985
  • Board certified in Clinical Biology, University Paris Descartes, 1985
  • Master of Haemostasis and Coagulation, Paris VII University, 1988
  • PhD, Paris XIII University, 1991
  • Research Supervisor Qualification, Paris Descartes University, 1996
  • Cell Therapy Paris VII University Degree, 1999

Work experience

  • Residency, Biology, 1982-1986
  • Praticien Hospitalier in Haematology, 1989
  • Associate professor, Paris Descartes University, 1990-2002
  • Professor of Haematology, Paris Descartes University, 2003

Membership and responsibilities

  • Member of University Paris Descartes scientific committee
  • « Commission Médicale d’Etablissement » of AP-HP
  • Responsible of the Haematology teaching department at the Faculty of Pharmacy
  • Responsible Paris Descartes of the Master 2 “Pharmaceutical Biotechnology and Innovative Therapies”
  • Regular reviewer for: Blood, ATVB, J Thromb Haemostas, Thromb Haemost etc
  • Member of Société Française d’Hématologie (SFH), Groupe d’Etudes sur l’Hémostase et la Thrombose (GEHT), Collège Français de Pathologie Vasculaire (SFPV)


  • International publications: 140 (total 210 Web of Science), French publications: 80, H-index : 31, Sum of Times Cited: 3949
  • Direction of 15 masters 2 and of 10 PhD thesis of Université Paris Descartes
  • Invited conferences (international meetings): 9
  • International meetings: 19 oral communications, 50 posters, Patents: 5

10 major publications

DUPONT A, FONTANA P, BACHELOT-LOZA C, RENY JL, BIECHE I, DESVARD F, AIACH M, GAUSSEM P. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003, 101 : 1833-40

FONTANA P, DUPONT A, GANDRILLE S, BACHELOT-LOZA C, RENY JL, AIACH M, GAUSSEM P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003, 108 : 989-95

GAUSSEM P, RENY JL, THALAMAS C, CHATELAIN N, KROUMOVA M, JUDE B, BONEU B, FIESSINGER JN. The specific thromboxane receptor antagonist S 18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005, 3, 1437-45

HULOT JS, BURA A, VILLARD E, AZIZI M, REMONES V, GOYENVALLE C, AIACH M, LECHAT P, GAUSSEM P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108 : 2244-47

SMADJA DM, BIECHE I, SILVESTRE JS, GERMAIN S, CORNET A, LAURENDEAU I, Duong Van Huyen JP, EMMERICH J, VIDAUD M, AIACH M, GAUSSEM P. Bone Morphogenetic Protein 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler Thromb Vasc Biol 2008, 28: 2137-43

GAUSSEM P, ALHENC-GELAS M, THOMAS JL, BACHELOT-LOZA C, REMONES V, DALI ALI F, AIACH M, SCARABIN PY. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol: a double-blind, randomized study. Thromb Haemost 2011, 105:560-7

Mumford AD, Nisar S,Darnige L, Bachelot-Loza C, Gandrille S, Zinzindoue F, Fischer A-M, Mundell SJ, Gaussem P. Platelet dysfunction associated with the novel Trp29Cys thromboxane A2 receptor variant. J Thromb Haemost 2013, 11: 547-54

GODIER A, TAYLOR G, GAUSSEM P. Inefficacy of platelet transfusion to reverse ticagrelor. N Eng J Med 2015, 372:196-7

DECOUTURE B, DREANO E, BELLEVILLE-ROLLAND T, KUCI O, DIZIER D, BAZAA A, COQUERAN B, LOMPRE AM, DENIS CV, HULOT JS, BACHELOT-LOZA C, GAUSSEM P. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood 2015, 126: 1823-30

KOSSOROTOFF M, DE MONTALEMBERT M, LASNE D, BROUSSE V, CURIS E, SMADJA DM, LACROIX R, BERTIL S, MASSON E, DESGUERRE I, BONNET D, GAUSSEM P. CD34+ Hematopoietic stem cell count is predictive for thrombotic event occurrence in sickle cell disease children. Stem Cell Rev 2018, in Press